NAD+ Safety Warning and Therapeutic Potential

Preclinical study warns NAD+ boosters may help pancreatic cancer cells survive chemotherapy. Niagen launches pharma program NB4168 for Ataxia Telangiectasia. A 27-year-old died after unlicensed NAD+ IV. Dual nature of NAD+ biology remains a key tension. New education partnership signals field maturation.